Hôpital Louis

Mar 6, 2025 | onlinelibrary.wiley.com | François Meyer |Hôpital Louis |Juliette Cotte |Lucas Bento

1 Introduction For nearly 40 years, the artificial urinary sphincter (AUS) has been the gold standard treatment in male patients with mild or severe stress urinary incontinence (SUI). The AMS 800 AUS (Boston Scientific, Marlborough, Massachusetts, MA, USA) is the most widely used device for the treatment of moderate to severe SUI in men, with no major recent modification of the device itself. Most studies are retrospective, but large cohorts have been published [1-3].

Mar 6, 2025 | onlinelibrary.wiley.com | François Meyer |Hôpital Louis |Juliette Cotte |Lucas Bento

1 Introduction For nearly 40 years, the artificial urinary sphincter (AUS) has been the gold standard treatment in male patients with mild or severe stress urinary incontinence (SUI). The AMS 800 AUS (Boston Scientific, Marlborough, Massachusetts, MA, USA) is the most widely used device for the treatment of moderate to severe SUI in men, with no major recent modification of the device itself. Most studies are retrospective, but large cohorts have been published [1-3].

Jan 28, 2025 | academic.oup.com | Foster City |Hôpital Louis

Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described. CAPELLA enrolled viremic HTE PWH with resistance to 2 or more drugs per class in at least 3 of the 4 main drug classes.